Brexpiprazole in the treatment of schizophrenia: pharmacology, efficacy, and side effects profile
Bibliographic record
Abstract
serotonin receptors; it also has antagonistic effects against 5-HT 2A , 5-HT 2B , 5-HT 7 , H 1 and M 1 receptors.It is metabolised mainly by CYP3A4 and CYP2D6 enzymes, excreted via the liver and the kidneys, and has a half-life of 96 hours.At doses of 2-4 mg/d, it is clinically effective in treating acute episodes of schizophrenia as it alleviates psychotic symptoms and improves psychosocial functioning.It also shows efficacy in maintenance treatment at doses of 1 to 4 mg/d, delaying relapse as compared to a placebo.Brexpiprazole is well tolerated by patients in both acute and maintenance treatment.It is characterised by a lack of effect on metabolic profile, prolactin levels, and QTc interval, as well as a small effect on body weight and a low risk of akathisia.Conclusions.Brexpiprazole is an effective medication in the treatment of schizophrenia.Among other drugs, it is distinguished by its favourable side effect profile, especially by a lack of metabolic side effects.With its set of features, it expands the range of therapeutic options in schizophrenia. StreSzczenieCel. Celem pracy jest przegląd istotnych klinicznie aspektów aktualnej wiedzy na temat brekspiprazolu w leczeniu schizofrenii -szczególnie jego właściwości farmakologicznych, skuteczności w leczeniu zaostrzeń i działania podtrzymującego remisję, a także profilu działań niepożądanych. AbStrActObjectives.This paper aims to review clinically relevant aspects of the current knowledge of brexpiprazole in the treatment of schizophrenia, particularly its pharmacological properties, efficacy in the treatment of exacerbations and maintenance of remission, as well as its side effects profile.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.006 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".